Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Evaluation of Active Hexose Correlated Compound (AHCC) in Combination With Anticancer Hormones in Orthotopic Breast Cancer Models.

Mathew L, Gaikwad A, Gonzalez A, Nugent EK, Smith JA.

Integr Cancer Ther. 2017 Sep;16(3):300-307. doi: 10.1177/1534735417704948. Epub 2017 Apr 25.

2.
3.

Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.

Jelovac D, Macedo L, Goloubeva OG, Handratta V, Brodie AM.

Cancer Res. 2005 Jun 15;65(12):5439-44.

4.

The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens.

Brodie AH, Jelovac D, Long B.

J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):283-8.

PMID:
14623522
5.

Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer.

Dowsett M, Pfister C, Johnston SR, Miles DW, Houston SJ, Verbeek JA, Gundacker H, Sioufi A, Smith IE.

Clin Cancer Res. 1999 Sep;5(9):2338-43.

7.

The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer.

Lu Q, Liu Y, Long BJ, Grigoryev D, Gimbel M, Brodie A.

Breast Cancer Res Treat. 1999 Sep;57(2):183-92.

PMID:
10598045
8.

Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach.

Itoh T, Karlsberg K, Kijima I, Yuan YC, Smith D, Ye J, Chen S.

Mol Cancer Res. 2005 Apr;3(4):203-18.

9.

L-BLP25 vaccine plus letrozole induces a TH1 immune response and has additive antitumor activity in MUC1-expressing mammary tumors in mice.

Mehta NR, Wurz GT, Burich RA, Greenberg BE, Griffey S, Gutierrez A, Bell KE, McCall JL, Wolf M, DeGregorio M.

Clin Cancer Res. 2012 May 15;18(10):2861-71. doi: 10.1158/1078-0432.CCR-12-0168. Epub 2012 Mar 20.

10.

Evaluation Fucoidan Extracts From Undaria pinnatifida and Fucus vesiculosus in Combination With Anticancer Drugs in Human Cancer Orthotopic Mouse Models.

Burney M, Mathew L, Gaikwad A, Nugent EK, Gonzalez AO, Smith JA.

Integr Cancer Ther. 2018 Sep;17(3):755-761. doi: 10.1177/1534735417740631. Epub 2017 Nov 20.

11.

Aromatase and breast cancer.

Brodie A, Sabnis G, Jelovac D.

J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):97-102.

12.

Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model.

Long BJ, Jelovac D, Handratta V, Thiantanawat A, MacPherson N, Ragaz J, Goloubeva OG, Brodie AM.

J Natl Cancer Inst. 2004 Mar 17;96(6):456-65.

PMID:
15026471
13.

Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer.

Ingle JN, Suman VJ, Johnson PA, Krook JE, Mailliard JA, Wheeler RH, Loprinzi CL, Perez EA, Jordan VC, Dowsett M.

Clin Cancer Res. 1999 Jul;5(7):1642-9.

14.

New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.

Hole S, Pedersen AM, Hansen SK, Lundqvist J, Yde CW, Lykkesfeldt AE.

Int J Oncol. 2015 Apr;46(4):1481-90. doi: 10.3892/ijo.2015.2850. Epub 2015 Jan 26.

15.

The effects of aromatase inhibitors and antiestrogens in the nude mouse model.

Lu Q, Yue W, Wang J, Liu Y, Long B, Brodie A.

Breast Cancer Res Treat. 1998 Jul;50(1):63-71.

PMID:
9802621
16.

Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole.

Jelovac D, Sabnis G, Long BJ, Macedo L, Goloubeva OG, Brodie AM.

Cancer Res. 2005 Jun 15;65(12):5380-9.

17.

Model systems: mechanisms involved in the loss of sensitivity to letrozole.

Brodie A, Jelovac D, Sabnis G, Long B, Macedo L, Goloubeva O.

J Steroid Biochem Mol Biol. 2005 May;95(1-5):41-8.

PMID:
15967659
18.

Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer.

Brodie A, Lu Q, Liu Y, Long B, Wang JP, Yue W.

Oncology (Williston Park). 1998 Mar;12(3 Suppl 5):36-40.

19.

Optimal combination of radiotherapy and endocrine drugs in breast cancer treatment.

Zeng ZJ, Li JH, Zhang YJ, Zhao ST.

Cancer Radiother. 2013 Jun;17(3):208-14. doi: 10.1016/j.canrad.2013.01.014. Epub 2013 May 7.

PMID:
23664221
20.

Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer.

Folkerd EJ, Dixon JM, Renshaw L, A'Hern RP, Dowsett M.

J Clin Oncol. 2012 Aug 20;30(24):2977-80. doi: 10.1200/JCO.2012.42.0273. Epub 2012 Jul 16.

PMID:
22802308

Supplemental Content

Support Center